Afabicin

Afabicin (Debio 1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 is an inhibitor FabI, an enzyme critical to fatty acid biosynthesis in staphylococci. IC50 & Target: FabI, Bacterial^[1] In Vitro: Afabicin (Debio1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 inhibits FabI, an enzyme critical to fatty acid biosynthesis in staphylococci. Debio1452 is highly active against staphylococci isolates, with MIC₅₀ and MIC₉₀ values of 0.015 μg/mL and 0.12 μg/mL, respectively. Debio1452 also inhibits S. aureus, with MICs of ≤0.12 μg/mL and MIC₅₀ and MIC₉₀ values of 0.004 μg/mL and 0.008 μg/mL, respectively^[1].